zurück

Pembrolizumab (new indication: small intestine cancer with MSI-H or dMMR tumors, pretreated patients)

 

Subject:

  • Active Sustance: Pembrolizumab
  • Name: Keytruda®
  • Therapeutic area: Small intestine cancer 
  • Pharmaceutical company: MSD Sharp & Dohme GmbH

 

Time table:

  • Start: 01.08.2022
  • Publication of assessment: 01.11.2022
  • End of public hearing: 22.11.2022
  • Final decision by G-BA: middle of January 2023

 

Comparative therapy:

  • Therapy at the physician's discretion, appropriate therapies include:
    • 5-fluorouracil + folinic acid + irinotecan (FOLFIRI) OR
    • irinotecan OR
    • nab-paclitaxel OR
    • nivolumab ± ipilimumab OR
    • Best Supportive Care